Press Releases

First Previous Next End

November 30, 2016

Provectus Biopharmaceuticals, Inc. Announces Notification of NYSE MKT Listing Deficiency

Provectus today announced receipt of notification (the "Deficiency Letter") from the NYSE MKT LLC that the Company is not in compliance with certain NYSE MKT continued listing standards relating to stockholders' equity.

November 14, 2016

Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 at Society for Immunotherapy of Cancer 2016 Annual Meeting

Provectus today announced the presentation of data on PV-10 at the Society for Immunotherapy of Cancer 2016 Annual Meeting.

November 10, 2016

Provectus Biopharmaceuticals Reports Third Quarter 2016 Financial Results

Provectus today announced its financial results for the quarter ended September 30, 2016.

November 2, 2016

Provectus Biopharmaceuticals Announces Data on PV-10 for Treatment of Pancreatic Cancer Scheduled for Poster Presentation at 31st SITC Annual Meeting

Provectus today announced that researchers will present data on the treatment of pancreatic cancer with PV-10, an investigational ablative immunotherapy under development by Provectus for solid tumor cancers, at the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC).

October 27, 2016

Provectus Biopharmaceuticals to Present at Sidoti's Fall 2016 Emerging Growth Conference, November 1, 2016

Provectus today announced that it will present at Sidoti and Company's Fall 2016 Emerging Growth Conference.

October 25, 2016

Provectus Biopharmaceuticals Will Hold Its 2016 Third Quarter Business Update Conference Call on Monday, November 14, 2016, at 4 PM Eastern Standard Time

Provectus announced today that it will host its 2016 third quarter business update conference call on Monday, November 14, 2016 at 4 pm Eastern Standard Time.

October 14, 2016

Trading in Provectus Biopharmaceuticals Common Stock and Warrants Suspended by NYSE MKT

Provectus today confirmed that the Company received a notice dated October 13, 2016 from the staff of NYSE Regulation, Inc. ("NYSE Regulation") indicating that it has determined to suspend trading of the Company's common stock trading under the symbol "PVCT" and its class of warrants trading under the symbol "PVCTWS" immediately and to commence proceedings to delist the Company's common stock and warrants from NYSE MKT LLC ("NYSE MKT").

October 11, 2016

Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 at European Society of Medical Oncology 2016 Congress Now Available Online

Provectus today announced that the poster presented at the European Society of Medical Oncology 2016 Congress is now available online.

October 6, 2016

Provectus Biopharmaceuticals Files Registration Statement for Rights Offering to Existing Stockholders

Provectus today announced that it filed a registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") for a rights offering to its existing stockholders.

September 27, 2016

Provectus Biopharmaceuticals Announces Acceptance of Abstract for Poster Presentation at 31st SITC Annual Meeting

Provectus today announced that the Society for Immunotherapy of Cancer has accepted an abstract for a poster presentation related to the use of PV-10, an investigational ablative immunotherapy under development by Provectus for solid tumor cancers, in the treatment of pancreatic cancer.

September 8, 2016

Provectus Biopharmaceuticals to Present at Rodman & Renshaw's 18th Annual Global Investment Conference

Provectus today announced that it will present at Rodman & Renshaw's 18th Annual Global Investment Conference.

August 30, 2016

Provectus Biopharmaceuticals, Inc. Announces Closing of Public Offering

Provectus today announced that it has completed its public offering of 240,000 shares of Series B Convertible Preferred Stock and warrants to purchase 24,000,000 shares of common stock at a price to the public of $25.00 for a combination of one share of Series B Convertible Preferred Stock and 100 warrants to purchase one share of common stock each.

August 25, 2016

Provectus Biopharmaceuticals, Inc. Announces Pricing of Public Offering to Raise $6 Million

Provectus today announced the pricing of a "best efforts" public offering of 240,000 shares of Series B Convertible Preferred Stock.

August 24, 2016

Provectus Biopharmaceuticals, Inc. Announces Proposed Public Offering of Preferred Stock and Warrants

Provectus today announced that it intends to offer and sell shares of its Series B Convertible Preferred Stock and warrants to purchase common stock, subject to market and other conditions, in a "best efforts" public offering. Provectus intends to use the net proceeds of the offering for clinical development, working capital and general corporate purposes.

August 23, 2016

Provectus Biopharmaceuticals, Inc. Receives Patent from USPTO Related to Rose Bengal Analogs

Provectus today announced that it has received a U.S. patent covering additional aspects of its process for synthesizing halogenated xanthenes, the family of compound to which rose bengal belongs. The patent covers use of certain halogenated xanthenes in pharmaceutical compositions and as medicaments.

August 9, 2016

Provectus Biopharmaceuticals, Inc. Reports Second Quarter 2016 Financial Results

Provectus today announced its financial results for the quarter ended June 30, 2016.

August 1, 2016

Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 for Melanoma at European Society for Medical Oncology 2016 Congress

Provectus today announced that a poster presentation titled "Intralesional rose bengal for stage III and IV melanoma" is to be presented at the European Society for Medical Oncology 2016 Congress on October 9, 2016, in Hall E of the Bella Center in Copenhagen, Denmark.

July 20, 2016

Provectus Biopharmaceuticals Will Hold Its 2016 Second Quarter Business Update Conference Call on Wednesday, August 10, 2016, at 4 PM Eastern Daylight Time

Provectus announced today that it will host its 2016 second quarter business update conference call on Wednesday, August 10, 2016 at 4 pm Eastern Daylight Time.

July 18, 2016

Provectus Biopharmaceuticals Receives Patent Allowance for Use of Halogenated Xanthenes in Pharmaceutical Compositions and as Medicaments

Provectus today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office covering additional aspects of its process for synthesizing halogenated xanthenes, the family of compound to which rose bengal belongs. The allowed claims cover use of certain halogenated xanthenes in pharmaceutical compositions and as medicaments.

July 14, 2016

Provectus Biopharmaceuticals Establishes Australian Subsidiary

Provectus today announced that it has formed an Australian subsidiary, Provectus Biopharmaceuticals Australia Pty Ltd. In addition, the Company is opening a Sydney office in New South Wales.

First Previous Next End